Taryn Williams1, Michael McCaul2, Guido Schwarzer3, Andrea Cipriani4,5, Dan J Stein1,6, Jonathan Ipser1. 1. Department of Psychiatry and Neuroscience Institute, University of Cape Town, South Africa. 2. Biostatistics Unit, Division of Epidemiology and Biostatistics, Department of Global Health, Universiteit Stellenbosch University, Cape Town, South Africa. 3. Institute of Medical Biometry and Statistics Faculty of Medicine and Medical Center, University of Freiburg, Germany. 4. Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. 5. Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK. 6. SA MRC Unit on Risk & Resilience in Mental Disorders.
Abstract
OBJECTIVE: The aim of this paper was to provide a systematic review and update on the pharmacotherapy of social anxiety disorder (SAD), including the efficacy and tolerability of these agents, the ranking of interventions, and the grading of results by quality of evidence. METHODS: The Common Mental Disorder Controlled Trial Register and two trial registries were searched for randomised controlled trials (RCTs) comparing any pharmacological intervention or placebo in the treatment of SAD. We performed a standard pairwise meta-analysis using a random effects model and carried out a network meta-analysis (NMA) using the statistical package, R. Quality of evidence was also assessed. RESULTS: We included 67 RCTs in the review and 21 to 45 interventions in the NMA. Paroxetine was most effective in the reduction of symptom severity as compared to placebo. Superior response to treatment was also observed for paroxetine, brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline. Higher dropout rates were found for fluvoxamine. Brofaromine, escitalopram, fluvoxamine, paroxetine, pregabalin, sertraline, and venlafaxine performed worse in comparison to placebo for the outcome of dropouts due to adverse events. Olanzapine yielded a relatively high rank for treatment efficacy and buspirone the worse rank for dropouts due to any cause. CONCLUSION: The differences between drugs and placebo were small, apart from a significant reduction in symptom severity and response for paroxetine. We suggest paroxetine as a first-line treatment of SAD, with the consideration of future research on the drug olanzapine as well as brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline because we observed a response to treatment.
OBJECTIVE: The aim of this paper was to provide a systematic review and update on the pharmacotherapy of social anxiety disorder (SAD), including the efficacy and tolerability of these agents, the ranking of interventions, and the grading of results by quality of evidence. METHODS: The Common Mental Disorder Controlled Trial Register and two trial registries were searched for randomised controlled trials (RCTs) comparing any pharmacological intervention or placebo in the treatment of SAD. We performed a standard pairwise meta-analysis using a random effects model and carried out a network meta-analysis (NMA) using the statistical package, R. Quality of evidence was also assessed. RESULTS: We included 67 RCTs in the review and 21 to 45 interventions in the NMA. Paroxetine was most effective in the reduction of symptom severity as compared to placebo. Superior response to treatment was also observed for paroxetine, brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline. Higher dropout rates were found for fluvoxamine. Brofaromine, escitalopram, fluvoxamine, paroxetine, pregabalin, sertraline, and venlafaxine performed worse in comparison to placebo for the outcome of dropouts due to adverse events. Olanzapine yielded a relatively high rank for treatment efficacy and buspirone the worse rank for dropouts due to any cause. CONCLUSION: The differences between drugs and placebo were small, apart from a significant reduction in symptom severity and response for paroxetine. We suggest paroxetine as a first-line treatment of SAD, with the consideration of future research on the drug olanzapine as well as brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline because we observed a response to treatment.
Entities:
Keywords:
network meta-analysis; social anxiety disorder; systematic review
Authors: James S W Hong; Lauren Z Atkinson; Paul J Harrison; Andrea Cipriani; Noura Al-Juffali; Amine Awad; John R Geddes; Elizabeth M Tunbridge Journal: Mol Psychiatry Date: 2021-11-24 Impact factor: 13.437
Authors: Dmitriy Matveychuk; Erin M MacKenzie; David Kumpula; Mee-Sook Song; Andrew Holt; Satyabrata Kar; Kathryn G Todd; Paul L Wood; Glen B Baker Journal: Cell Mol Neurobiol Date: 2021-04-10 Impact factor: 5.046